Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy.

MLA

Puolakkainen, Tero, et al. “Treatment with Soluble Activin Type IIB-Receptor Improves Bone Mass and Strength in a Mouse Model of Duchenne Muscular Dystrophy.” BMC Musculoskeletal Disorders, vol. 18, Jan. 2017, pp. 1–11. EBSCOhost, https://doi.org/10.1186/s12891-016-1366-3.

APA

Puolakkainen, T., Hongqian Ma, Kainulainen, H., Pasternack, A., Rantalainen, T., Ritvos, O., Heikinheimo, K., Hulmi, J. J., Kiviranta, R., & Ma, H. (2017). Treatment with soluble activin type IIB-receptor improves bone mass and strength in a mouse model of Duchenne muscular dystrophy. BMC Musculoskeletal Disorders, 18, 1–11. https://doi.org/10.1186/s12891-016-1366-3

Chicago

Puolakkainen, Tero, Hongqian Ma, Heikki Kainulainen, Arja Pasternack, Timo Rantalainen, Olli Ritvos, Kristiina Heikinheimo, Juha J. Hulmi, Riku Kiviranta, and Hongqian Ma. 2017. “Treatment with Soluble Activin Type IIB-Receptor Improves Bone Mass and Strength in a Mouse Model of Duchenne Muscular Dystrophy.” BMC Musculoskeletal Disorders 18 (January): 1–11. doi:10.1186/s12891-016-1366-3.